Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Web Sites |
     
  3. Global Business Websites |
     
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Your Health

Contact Us

Sanofi Ireland Ltd.

18 Riverwalk
Citywest Business Campus
Dublin 24

Tel : + 353 (0)1 403 5600

Content :

Diabetes

Metabolic Disorders

Sanofi has an 85-year commitment to improving the health and wellbeing of diabetes patients.

 

Faced with the public health challenge of the worldwide diabetes epidemic, Sanofi aims to lead the fight against diabetes with a portfolio approach that includes Apidra® (insulin gluisine), Lantus® (insulin glargine) and Insuman® (human insulin).  Our current insulins are available in one or more of our most modern user friendly devices, CLIKSTAR® and SOLOSTAR®.

In Ireland, the number of people with diabetes is estimated at 191,380 and is expected to reach 278,850 by 2030.  Sanofi drive the agenda for more effective managemet of this condition through major awareness campaigns to highlight the importance of mainting good glycaemic control and to encourage screening, good nutrition and physical exercise.

Sanofi offers the information on this website for general education and information purposes only.  product information is specific to Ireland and is not intended to replace the advice of a healthcare professional.  For information on Sanofi's product portfolio in Ireland please visit the Our Products section of this website.

Updated June 28, 2013

Module :